19th week of 2011 patent applcation highlights part 46 |
Patent application number | Title | Published |
20110111994 | PROCESS FOR THE PREPARATION OF POLYALKENYL SUCCINIC ANHYDRIDES - A polyalkenyl succinic anhydride is prepared with low amounts of resinous or chlorinated byproducts in a two-step process whereby a polyalkene is first reacted with an unsaturated organic acid in a thermal ene reaction, followed with exposure to a gaseous halogen in presence of an additional amount of the unsaturated organic acidic reagent. The foregoing process produces a polyisobutenyl succinic anhydride having a high ratio of succinic anhydride functional groups to polyisobutenyl backbone groups. Such a polyisobutenyl succinic anhydride is particular suitable for the production of oil-soluble hydrocarbyl succinimides that have good dispersant properties when added to lubricating oil compositions. | 2011-05-12 |
20110111995 | GREASE COMPOSITION AND PROCESS FOR PRODUCTION THEREOF - In this grease composition, a grease produced by mixing at least one base oil selected from a mineral oil-type lubricant base oil, a synthetic lubricant base oil, and a biodegradable lubricant base oil with a thickener is compounded with a wax and water, and an additive such as a surfactant and a defoamer is optionally compounded therewith. A soap containing a calcium sulfonate complex is used as the thickener. A carnauba wax is preferably used as the wax. Since this grease composition is mainly composed of a grease and a wax, the grease composition extremely facilities its removal operation after application, is environmentally friendly, and has extremely excellent anti-corrosion performance. When the grease composition is used by being applied to a base material of an object to be welded, an effect of preventing the adhesion of welding spatters can be obtained. | 2011-05-12 |
20110111996 | Lubricant Compositions - A lubricant composition characterized by the Society of Automotive Engineers (“SAE”) as 75W-140 capable of meeting the American Petroleum Institute's (“API”) GL-5 performance classification requirements for use in association with a device involving metal to metal contact of moving parts comprising: (a) base-stock comprising (i) at least one relatively low viscosity polyalphaolefin, and (ii) at least one diester; (b) viscosity improver comprising (i) at least one relatively high viscosity polyalphaolefin, and (ii) polyisobutylene; and (c) a performance additive comprising at least one additive effective to improve at least one property of the lubricant and/or the performance of the equipment in which the lubricant is to be used. | 2011-05-12 |
20110111997 | AMINIC ANTIOXIDANTS TO MINIMIZE TURBO SLUDGE - A turbo-charged, sump-lubricated internal combustion engine which is susceptible to contamination of lubricant with liquid fuel, is lubricated with a lubricant which contains an amount of an aminic antioxidant, optionally in the absence of a phenolic antioxidant, thereby reducing the deterioration of said lubricant and formation of turbo sludge. | 2011-05-12 |
20110111998 | MODIFICATION OF PARTICULATE-STABILISED FLUID-FLUID INTERFACES - The invention provides a composition comprising at least two immiscible fluid phases separated by a fluid-fluid interface, in which the interface is stabilised by an assembly of biopolymeric microparticles adsorbed at the interface, characterised in that the properties of the interface are modified via the association of at least one functional group on the biopolymer for example hydroxypropyl methyl cellulose phthalate with at least one ligand for example eosin. This enables, for example, the production of coloured emulsions and in particular coloured foams and bubbles. | 2011-05-12 |
20110111999 | HIGH-EFFICIENCY PERFUME CAPSULES - The present application relates to high efficiency particles and compositions, such as consumer products, comprising such high efficiency particles as well as processes for making and using such high efficiency particles and compositions comprising such high efficiency particles. Such high efficiency particles and compositions provide enhanced benefit agent delivery to a situs that is treated with such high efficiency particles and compositions. | 2011-05-12 |
20110112000 | BRAIDED HAIR WASHING METHOD - A braided hair washing method includes washing braided hair using a washing agent that includes a microbubble washing composition and microbubbles, the microbubble washing composition including a protease and a lipase. The braided hair washing method can conveniently and effectively wash braided hair without collapsing the hairstyle. | 2011-05-12 |
20110112001 | SOAP RECYCLING SYSTEM AND METHOD - In one embodiment, a method for recycling soap includes scraping the surface of a soap bar using a bladed implement; soaking the soap bar in a cleansing solution including dimethyl benzylammonium chlorides monohydrate; placing the soap bar on a rack in a Rational Clima Plus Combi unit; placing a pan under the rack; steaming the soap bar using the Rational Clima Plus Combi unit for five minutes at 212° F.; cooling the soap bar in a refrigerator unit at 38° F. for at least seven minutes; and packaging the soap for reuse. | 2011-05-12 |
20110112002 | METHODS OF CLEANING COMPONENTS HAVING INTERNAL PASSAGES - Methods are provided for cleaning a component having internal passages. A method includes contacting the component with an aqueous hydrogen fluoride solution without agitating the solution for a time period in a range of about 20 minutes to about an hour to dissolve a solid piece of blockage material blocking at least a portion of the internal passages, the aqueous hydrogen fluoride solution comprising, by volume, about 40 percent to about 60 percent hydrogen fluoride and optionally, a corrosion inhibitor, and the blockage material comprising a silicate and rinsing the component with water to remove at least a portion of the aqueous hydrogen fluoride solution from surfaces of the component defining at least a portion of the internal passages. | 2011-05-12 |
20110112003 | ENHANCED DISPENSING OF SOLID COMPOSITIONS - A solid detergent composition includes an ethoxylated and propoxylated surfactant, an alkalinity source, a solidification agent and a chelating agent. The ethoxylated and propoxylated surfactant can include a surfactant blend of naturally sourced ethoxylated and propoxylated surfactants. | 2011-05-12 |
20110112004 | COMPOSITION AND METHODS FOR REMOVAL OF POLYMERIZED NON-TRANS FATS - The invention is a composition and method for removing soils containing polymerized non-trans fats from surfaces. The composition comprises a polymer and sequentrant, wherein the polymer is oleophobic and hydrophilic. Optionally, the composition may also include a wetting agent. The composition may be used by applying it to a clean surface as a pretreatment so that when said surface is soiled or contaminated with polymerized non-trans fats it may be easily removed with water. | 2011-05-12 |
20110112005 | Laundry Detergent Composition - A laundry detergent composition having: (a) from about 1 wt % to about 20 wt % by weight of an alkyl ether sulfate of the general formula: R—(OCH | 2011-05-12 |
20110112006 | IMPROVEMENTS IN ACIDIC HARD SURFACE CLEANING COMPOSITIONS - Provided are an acidic hard surface cleaning composition which includes: a surfactant system which includes one or more of anionic, cationic, nonionic, amphoteric or zwitterionic surfactants in amounts of at least 0.01% wt, preferably in amounts of between in excess of 1% wt, to 30% wt., with the proviso that if a cationic surfactant is present, is it present in an amount of in excess of 1% wt, more preferably in an amount of at least 1.1% wt; a volatile hydrocarbon having a volatility greater than that of water, and preferably wherein the volatile hydrocarbon has a vapor pressure of 0.2 mniHg or more at 20° C. in amount effective to impart motility when the composition is applied as a film or laminar layer to a hard surface at normal atmospheric conditions (‘sea level’) and at ambient temperature (approx. 20° C.); an acid constituent which includes one or more acids, including one or more organic or inorganic acids in an amount effective to impart an acidic pH to the composition; optionally, when the compositions of the invention comprise more than 1% wt. of a cationic surfactant, and/or when the compositions of the invention comprise one or more anionic, amphoteric or zwitterionic surfactants in amount of at least 0.01% wt, the compositions of the invention may include an amphiphilic solvent constituent; further optionally, one or more further constituents including coloring agents, fragrances and fragrance solubilizers, viscosity modifying agents including one or more thickeners, pH adjusting agents and pH buffers including organic and inorganic salts, optical brighteners, organic solvents, opacifying agents, hydrotropes, abrasives, and preservatives, as well as other optional constituents known to the art; and water in an amount of at least 80% wt, preferably in an amount of at least 85% wt. based on the total weight of the composition of which it forms a pan. wherein the composition exhibits self-induced movement when the composition is applied as a film or laminar layer onto a hard surface. | 2011-05-12 |
20110112007 | ALKYL POLYGLUCOSIDES AND A PROPOXYLATED-ETHOXYLATED EXTENDED CHAIN SURFACTANT - A cleaning composition includes an alkyl polyglucoside, an ethoxylated, propoxylated extended chain surfactant having between 6 and 10 carbon atoms and a cloud point of about 42° C. or less, a water conditioning agent and water. In one embodiment, the cleaning composition is substantially free of alkyl phenol ethoxylates. The cleaning composition is capable of removing soils including up to 20% proteins. | 2011-05-12 |
20110112008 | SULFONATED ALKYL POLYGLUCOSIDE USE FOR ENHANCED FOOD SOIL REMOVAL - A cleaning composition including a sulfonated functionalized alkyl polyglucoside, a co-surfactant, a water conditioning agent and water. The sulfonated functionalized alkyl polyglucoside is one of a C | 2011-05-12 |
20110112009 | PHOSPHATE FUNCTIONALIZED ALKYL POLYGLUCOSIDES USED FOR ENHANCED FOOD SOIL REMOVAL - A cleaning composition including a C | 2011-05-12 |
20110112010 | OCTANOIC ACID FORMULATIONS AND METHODS OF TREATMENT USING THE SAME - The invention features pharmaceutical formulations containing octanoic acid or a salt or ester thereof. The pharmaceutical formulations are useful for the treatment of involuntary tremors. | 2011-05-12 |
20110112011 | PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE - Disclosed are pharmaceutical compositions containing, as active ingredients, a mixture of a corticosteroid and a kinin B2 receptor antagonist. Said compositions have proved particularly effective, especially in the treatment of inflammatory disorders such as asthma, ophthalmic or dermatological disorders and, above all, as regards the joints, arthritis. | 2011-05-12 |
20110112012 | Novel Protein for Binding Bacillus Thuringiensis Cry Toxins and Fragments of Cadherins for Enhancing Cry Toxicity Against Dipterans - The subject invention relates in part to a novel protein for binding | 2011-05-12 |
20110112013 | Novel Bacillus thuringiensis Gene with Lepidopteran Activity - The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of | 2011-05-12 |
20110112014 | SUPPLEMENTATION OF PROPANE-1,2,3-TRIOL AND WATER IN FASTING SUBJECTS - Glycerol-containing solutions are useful for improving both the metabolic and hydration state of fasting individuals. The same solutions can be utilized in persons facing situations where urination is impossible or inconvenient. | 2011-05-12 |
20110112015 | USE OF GLIS3 FOR PREPARING FUNCTIONAL PANCREATIC BETA-CELLS - The present invention relates to a method of diagnosis of neonatal diabetes, congenital hypothyroidism and congenital glaucoma, comprising detecting the presence of a mutation in the GLIS3 gene and to a method for preparing functional pancreatic beta-cells by culturing human multipotent or pluripotent cells, such as embryonic stem cells (ES-cells) or human somatic stem cells in a culture medium comprising a effective amount of GLIS3 to induce said cells differenciation into functional pancreatic beta-cells producing insulin. It also relates to a pharmaceutical composition comprising GLIS3 as active ingredient. | 2011-05-12 |
20110112016 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM - A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a T | 2011-05-12 |
20110112017 | COMPOSITIONS, METHODS AND USES FOR TREATING DIABETES - Embodiments herein concern compositions and methods for treating diabetes in a subject. | 2011-05-12 |
20110112018 | Method for the Treatment and/or Prophylaxis of Multiple Sclerosis, and Use of Erythropoietin for the Manufacture of a Medicament for the Intermittent and/or Intermittent Prophylaxis of Multiple Sclerosis - The present invention relates to a method for the treatment and/or prophylaxis of multiple sclerosis, and to the use of erythropoietin for this purpose and for the manufacture of a medicament for the intermittent treatment and/or intermittent prophylaxis of multiple sclerosis. | 2011-05-12 |
20110112019 | METHOD FOR PROMOTING HAIR GROWTH OR HAIR REGENERATION BY MAINTAINING OR INCREASING EXPRESSION OF CELL-ADHESION FACTOR - An object of the present invention is to promote hair growth or hair regeneration by promoting formation and/or regeneration of hair follicles. A method is provided for promoting formation and/or regeneration of hair follicles, comprising maintaining or increasing expression of one or a plurality of genes involved in cell adhesion in dermal papilla cells. | 2011-05-12 |
20110112020 | MEASUREMENT OF G-PROTEIN mRNA IN THE DIAGNOSIS OF GROWTH HORMONE INSUFFICIENCY - The present invention is directed towards a diagnostic test, treatment, and monitoring of treatment for growth hormone abnormalities including Growth Hormone Deficiency (“GHD”) as well as a kit comprising the necessary components of the present invention. G-protein expression and levels of mRNA are evaluated to determine if a patient has GHD or if treatment for GHD is effective. A G-protein agonist or antagonist is used to treat GHD by bringing G-protein expression and levels of mRNA into the normal range. | 2011-05-12 |
20110112021 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS - A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial. | 2011-05-12 |
20110112022 | Factor VIII Muteins with Reduced Immonugenicity - The invention relates to modified Factor VIII molecules with reduced N-linked glycosylation and reduced immunogenicity. The invention also relates to methods of using modified Factor VIII molecules, for example, to treat patients afflicted with hemophilia. | 2011-05-12 |
20110112023 | VON WILLEBRAND FACTOR OR FACTOR VIII AND VON WILLEBRAND FACTOR FOR THE TREATMENT OF COAGULOPATHY INDUCED BY INHIBITORS OF THROMBOCYTES - The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. | 2011-05-12 |
20110112024 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2011-05-12 |
20110112025 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2011-05-12 |
20110112026 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2011-05-12 |
20110112027 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2011-05-12 |
20110112028 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2011-05-12 |
20110112029 | LOW VISCOSITY COMPOSITIONS COMPRISING A PEGYLATED GLA-DOMAIN CONTAINING PROTEIN - The present invention relates to a method for lowering the viscosity of compositions comprising Vitamin K-dependent proteins. | 2011-05-12 |
20110112030 | METHODS OF TREATING OR PREVENTING STENT THROMBOSIS - The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation. | 2011-05-12 |
20110112031 | OPTIMIZED DENGUE VIRUS ENTRY INHIBITORY PEPTIDE (DN81) - The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds. | 2011-05-12 |
20110112032 | Regulation of Brain Natriuretic Peptide and Catecholamines for the Treatment of Cardiovascular Diseases - The present invention describes methods for treating heart diseases by pharmacological manipulation of intrinsic cardiac adrenergic cells. The activation or inhibition of δ-opioid receptors or selective β2-adrenergic receptor agonist in these cells can help regulate catecholamine synthesis and release in these cells. Thus drugs directed towards these receptors can be used in the treatment of heart diseases including acute and chronic congestive heart failure, as well as acute and chronic coronary artery disease. The present invention also describes a method of treating acute decompensated congestive heart failure using δ-opioid receptor agonists or selective β2-adrenergic receptor agonists to stimulate endogenous production of brain natriuretic peptide. This invention also provides a novel strategy for protection against myocardial ischemia through the specific activation of δ-opioid receptors or selective β2-adrenergic receptor agonists exclusively expressed by intrinsic cardiac adrenergic cells in human heart. The activation of intrinsic cardiac adrenergic cells by δ-opioid receptor stimulation enhances endogenous catecholamine release, which subsequently stimulates myocardial alpha 1-adrenoreceptors achieving myocardial protection in patients suffering from myocardial ischemia due to coronary artery disease. | 2011-05-12 |
20110112033 | COGNITIVE ENHANCEMENT AND COGNITIVE THERAPY USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID - This invention provides compounds, compositions and methods for treating a cognitive disorder or memory disorder in animals that result from aging or other neurodegenerative condition. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function. | 2011-05-12 |
20110112034 | Modulation of synaptogenesis - Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain but on at high levels in postnatal brain. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis. These findings have broad implications for a variety of clinical conditions, including traumatic brain injury, epilepsy, and other conditions where synapses fail to form or form inappropriately. Synaptogenesis is enhanced by contacting neurons with agents that are specific agonists or antagonists of thrombospondins. Conversely, synaptogenesis is inhibited by contacting neurons with inhibitors or antagonists of thrombospondins. | 2011-05-12 |
20110112035 | THERAPEUTIC USE OF A GROWTH FACTOR, METRNL - The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects. | 2011-05-12 |
20110112036 | PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED METHODS OF PREPARATION AND USE - Pharmaceutical compositions useful for hydrophobic agents paclitaxel, paclitaxel analogs and conjugates thereof (e g ANG1005) which do not contain Cremophor™ The compositions further comprise an optional tonicity agent, a buffering agent a bulking agent and a solubilizmg agent which is not Cremophor™ Methods of preparing said compositions and of said compositions in the treatment of cancer are also included. | 2011-05-12 |
20110112037 | CRYSTAL STRUCTURE - The invention provides a method of predicting a three dimensional structural representation of a target protein of unknown structure, or part thereof, comprising: providing the coordinates of the turkey β1-AR structure listed in Table A, Table B, Table C or Table D, optionally varied by a root mean square deviation of residue backbone atoms of not more than 1.235 A, or selected coordinates thereof; and predicting the three-dimensional structural representation of the target protein, or part thereof, by modelling the structural representation on all or the selected coordinates of the turkey β1-AR. The invention also provides the use of the turkey β1-AR coordinates to select or design one or more binding partners of β1-AR. | 2011-05-12 |
20110112038 | NOVEL NPR-B AGONISTS - Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. | 2011-05-12 |
20110112039 | Polysaccharides comprising carboxyl functional groups substituted via esterification by a hydrophobic alcohol - Polysaccharide including carboxyl functional groups. The polysaccharide being chosen from the group of anionic synthetic polysaccharides including 1,6 bonds obtained from neutral polysaccharides of which at least one of a carboxyl functional groups is esterified by a hydrophobic alcohol (-Ah) (residue of a hydrophobic alcohol). The hydrophobic alcohol (Ah) being grafted or bonded to the anionic polysaccharide by a function F (ester function), which results from coupling between the carboxylate function of the anionic polysaccharide and hydroxyl function of the hydrophobic alcohol. Carboxyl functions of anionic polysaccharide, which are not substituted, are in the form of carboxylate of a cation. The polysaccharide including carboxyl functional groups are amphiphilic at neutral pH. | 2011-05-12 |
20110112040 | SUPERCHARGED PROTEINS FOR CELL PENETRATION - Compositions, systems and related methods for delivering a supercharged protein or a complex of a supercharged protein and therapeutic agent (e g, nucleic acid, peptide, small molecule) to cells are disclosed. Superpositively charged proteins may be associated with nucleic acids (which typically have a net negative charge) via electrostatic interactions. The systems and methods may involve altering the primary sequence of a protein in order to “supercharge” the protein (e g, to generate a superpositively-charged protein). The compositions may be used to treat proliferative diseases, infectious diseases, cardiovascular diseases, inborn errors in metabolism, genetic diseases, etc. | 2011-05-12 |
20110112041 | Treatment of Male-Pattern Baldness by Local Induction of the Metabolic Defect of Fabry Disease - Compositions comprising inhibitors of lysosomal enzyme alpha-galactosidase A and their use to favor hair growth or to prevent hair loss are disclosed in the instant invention. The topical use of the composition of the instant invention directly inhibits scalp enzyme activity and is used in the treatment for male pattern baldness (androgenic alopecia) in men and women. | 2011-05-12 |
20110112042 | NOVEL FLAVONOL COMPOUNDS, A BIOACTIVE EXTRACT/FRACTION FROM ULMUS WALLICHIANA AND ITS COMPOUNDS FOR PREVENTION FOR TREATMENT OF OSTEO-HEALTH RELATED DISORDERS - The present invention provides a flavonol compound and a bioactive extract/fraction from | 2011-05-12 |
20110112043 | METHOD OF UTILIZING PHYSIOLOGICAL ACTIVITY OF RARE SACCHARIDE AND COMPOSITION CONTAINING RARE SACCHARIDE - A method of utilizing the physiological activity of a rare saccharide, wherein physiological-activity sensitive cells are treated with the rare saccharide to modify the function of the cells. A composition containing, as an active ingredient, a rare saccharide which is introduced into physiological-activity sensitive cells and has an effect of modifying the function of the cells. The cells are human cells. The composition is a functional food, a drug, or a cosmetic. The rare saccharide is a rare saccharide belonging to aldose and/or ketose. The aldose is D-allose, and the cells are selected from the group consisting of cancer-cell proliferation inhibitory activity sensitive cells and active-oxygen production inhibitory activity sensitive cells. The ketose is D-psicose, and the cells are selected from the group consisting of chemokine secretion inhibitory activity sensitive cells, microglia migration inhibitory activity sensitive cells, and hypoglycemic activity sensitive cells. | 2011-05-12 |
20110112044 | NOVEL USES OF D-MANNOPYRANOSE DERIVATIVES - The invention relates to the use of mannose-6-phosphate (M6P) and of certain derivatives thereof for controlling angiogenesis and ligament regeneration and/or cartilage reconstruction. The MP6 and certain derivatives thereof can particularly be used for preparing a pharmaceutical composition used for ligament regeneration and/or cartilage reconstruction. | 2011-05-12 |
20110112045 | CREAMY O/W EMULSION COMPOSITION AND PRODUCTION PROCESS THEREOF - A major object of the present invention is to provide a creamy O/W emulsion composition containing an adenosine phosphate ester, more specifically, to provide a creamy O/W emulsion composition containing an adenosine phosphate ester, which ensures emulsification stability and a superior feel during use. Specifically, the present invention provides a creamy O/W emulsion composition containing the following Components (A) to (F) at the following proportions based on its total amount: | 2011-05-12 |
20110112046 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS - This invention relates to novel phosphate-modified nucleosides, and methods for producing them, being useful for the prevention or treatment of a viral infection in a mammal, and for preparing oligonucleotides by DNA/RNA polymerase-dependent amplification, e.g. PCR. | 2011-05-12 |
20110112047 | METHODS FOR ENHANCING MUSCLE PERFORMANCE AND TONE - This disclosure concerns the use of agonists of AMP-activated protein kinase (AMPK) for improving exercise and modifying energy metabolism in a subject. The disclosure also relates to a combination of AMPK and peroxisome proliferator-activated receptor (PPAR) δ agonists for improving exercise performance in a subject, methods for identifying substance-enhanced exercise performance in a subject, and methods for identifying compounds that affect the interaction of PPARδ with exercise-induced kinases. | 2011-05-12 |
20110112048 | Use of beta-glucan on upper respiratory tract infection symptoms and psychological well-being - Studies involving placebo-controlled, double-blinded designs to evaluate the effect of beta-glucan compositions on upper-respiratory tract infections and psychological wellness were carried out. During the course of the reporting periods of these studies, subjects in the treatment groups reported fewer URTI symptoms, better overall health and a more positive psychological assessment based on a POMS survey. | 2011-05-12 |
20110112049 | METHODS OF PREVENTING OR TREATING DISEASES AND CONDITIONS USING COMPLEX CARBOHYDRATES - The invention relates to a method of preventing and treating diseases and conditions associated with allergies, autoimmunity, the adhesion cascade, the metastatic cascade or the coronary cascade comprising administering (i) at least one complex carbohydrate as the sole active ingredient, or (ii) at least one pharmaceutical composition which comprises as an active ingredient a pharmacologically effective amount of at least one low purity or cosmetic grade complex carbohydrate selected from the group consisting of oligosaccharides, sialylated oligosaccharides, polysaccharides and glycosaminoglycans, and an effective amount of at least one transdermal or transmucosal carrier in an amount effective to deliver the complex carbohydrate into the blood stream. | 2011-05-12 |
20110112050 | SEPARATION OF POLYSACCHARIDES BY CHARGE DENSITY GRADIENT - Methods and apparatus for the separation of polysaccharides, particular heparin products, and glycosylated molecules are provided. The separation is based on the molecular weight and charge, by application of an electric field across a low-friction matrix, modified with a charged separation agent comprising charged regions ordered in a monotonous sequence distributed throughout the matrix, to generate a charge density gradient formed when an external electric field is applied. Saccharides of different charges migrate differently across the porous matrix and immobilized by charge neutralization in different charge regions of the matrix. | 2011-05-12 |
20110112051 | Dipeptidyl Peptidase-IV Inhibitors - The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes. | 2011-05-12 |
20110112052 | SPIRO-OXINDOLE MDM2 ANTAGONISTS - Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases. | 2011-05-12 |
20110112053 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS - Disclosed herein are compositions and methods for decreasing vascular permeability in a blood vessel and treating or preventing conditions associated with defects or injuries of vascular endothelium. For example, the disclosed compositions and methods can be used to treat a vascular dysplasia such as cerebral cavernous malformation (CCM). These methods relate generally to the use of compositions that inhibit RhoA GTPase levels or activity, such as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. | 2011-05-12 |
20110112054 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells - The present invention describes organophosphorus compounds of general formula (I) | 2011-05-12 |
20110112055 | COMPOSITIONS AND METHODS FOR TREATING COLITIS - Disclosed herein are compositions and methods for treating colitis and other inflammatory bowel diseases, inter alia, indeterminate colitis, Crohn's disease, irritable bowel syndrome and ischemic colitis. | 2011-05-12 |
20110112056 | Use of Carbon-2-Modified-Vitamin D Analogs to Induce the Formation of New Bone - It has been discovered that the 2-carbon-modified derivatives of 1α,25-dihydroxyvitamin D | 2011-05-12 |
20110112057 | Sequential administration of 20,20,21,21,21-pentafluoro-17-hydroxy-11Beta-[4-(hydroxyacetyl)phenyl]-19- -nor-17Alpha-pregna-4,9-dien-3-one and one or more progestogens for the treatment of gynaecological disorders - The present invention relates to treatment regimes and combination products of 20,20,21,21,21-pentafluoro-17-hydroxy-11β-[4-(hydroxyacetyl)phenyl]-19-nor-17α-pregna-4,9-dien-3-one of the formula | 2011-05-12 |
20110112058 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER - Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer. | 2011-05-12 |
20110112059 | PHOTOACTIVATABLE ANTIMICROBIAL AGENTS AND THERAPEUTIC AND DIAGNOSTIC METHODS OF USING SAME - The present invention provides photosensitizer compounds for use in detecting beta-lactamase activity. Methods and kits that utilize the photosensitizer compounds of the invention for the detection of, quantitation of, and classification or typing of microbial beta-lactamases. | 2011-05-12 |
20110112060 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. | 2011-05-12 |
20110112061 | PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF - The present invention relates to a class of pyridazinones of formula I, which comprises 6-[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one as a mother nucleus, the preparation method thereof and the use thereof in manufacturing medicaments against tumors, especially liver cancer. | 2011-05-12 |
20110112062 | Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 - This invention relates to novel compounds of the Formula I, II, III, IHa, NIb, IV, IVa, IVb, IVc, IVd, IVe, V, Va, Vb1 V1, V1a, VIb, VII, Vi1a, VIIb, VIII, V111a, VIIIb, IX, IXa, X, and Xa, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell. | 2011-05-12 |
20110112063 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS - The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK). | 2011-05-12 |
20110112064 | Pyridyl Amide T-Type Calcium Channel Antagonists - The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 2011-05-12 |
20110112065 | MODULATORS OF DOPAMINE NEUROTRANSMISSION - The present invention relates to novel 1-(4H-1,3-benzodioxin-2-yl)methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically asdopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2011-05-12 |
20110112066 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF - An alkyl ether derivative represented by the following general formula [1] | 2011-05-12 |
20110112067 | Inhibitors of the Human Aldosterone Sythase CYP11B2 - The invention provides compounds of the general formula (I) | 2011-05-12 |
20110112068 | HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITORS - The described invention relates to novel human immunodeficiency virus protease inhibitors, pharmaceutical compositions containing at least one such inhibitor, methods of preparing such inhibitors, and methods of utilizing such inhibitors to treat HIV and HIV-related disorders. | 2011-05-12 |
20110112069 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES - The specification describes the use of selected purine derivatives for the treatment of hyperproliferative diseases. | 2011-05-12 |
20110112070 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES - The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity. | 2011-05-12 |
20110112071 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE - A compound represented by formula (I′): | 2011-05-12 |
20110112072 | THIOPHENYL AND PYRROLYL AZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF - The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT | 2011-05-12 |
20110112073 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF - The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity. | 2011-05-12 |
20110112074 | CHLOROTHIOPHENE-ISOXAZOLES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN - The present invention relates to compounds of the formula I, | 2011-05-12 |
20110112075 | CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN - The present invention relates to compounds of the formula I, | 2011-05-12 |
20110112076 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS - The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I). | 2011-05-12 |
20110112077 | Quinolizidinone m1 Receptor Positive Allosteric Modulators - The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 2011-05-12 |
20110112078 | NOVEL OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE - This invention relates to novel oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholin receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 2011-05-12 |
20110112079 | PHOSPHODIESTERASE INHIBITORS - The invention related to compounds for formula I useful for inhibiting phosphodiesterase-4. | 2011-05-12 |
20110112080 | OXAZOLINE DERIVATIVES - The invention relates to compounds of formula I | 2011-05-12 |
20110112081 | INHIBITORS OF JANUS KINASES - The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2). The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 and TYK2 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer. | 2011-05-12 |
20110112082 | CYCLIC CARBAZATE AND SEMICARBAZIDE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 - This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie),(If), (Ig), (Ih), (Ii), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell. | 2011-05-12 |
20110112083 | FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF - The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa. | 2011-05-12 |
20110112084 | Bicyclic androgen and progesterone receptor modulator compounds and methods - The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis. | 2011-05-12 |
20110112085 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2011-05-12 |
20110112086 | PYRIDINONE ANALOGS - The present invention provides pyridinone analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing pyridinone analogs, and methods of using the same. | 2011-05-12 |
20110112087 | Thia-triaza-cyclopentazulenes - The present invention encompasses compounds of general formula (1) | 2011-05-12 |
20110112088 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS - This invention relates to compounds of the formula: | 2011-05-12 |
20110112089 | Cysteine Protease Inhibitors - A compound of the formula II | 2011-05-12 |
20110112090 | Depsipeptides and Their Therapeutic Use - A Compound of structure (IX) or (X) or a pharmaceutically acceptable salt thereof, wherein: X is —C(═O)N(R | 2011-05-12 |
20110112091 | DERIVATIVES OF TETRABROMOBENZIMIDAZOLE, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, A METHOF OF USING THE SAME, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES, AND SERINE/THREONINE KINASES MODULATING AGENT - A derivative of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition, a method for using the same, a method for modulating or regulating serine/threonine kinases, and a serine/threonine kinases modulating agent. The invention relates to novel small-molecule compounds with kinase inhibitory activity, having superior properties as pharmaceutical agents, production method thereof and uses thereof. In particular, this invention relates to new derivatives of tetrabromobenzimidazole with Pim kinases inhibitory properties, which exhibits superior pharmacological actions, and can be useful for the treatment of disease conditions, especially cancers depending on Pim kinases, such as leukemias and prostate cancer. | 2011-05-12 |
20110112092 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS - The present invention relates to an adenosine A | 2011-05-12 |
20110112093 | PYRIMIDINYL-PIPERAZINES USEFUL AS D3/D2 RECEPTOR LIGANDS - The present invention relates to new dopamine D | 2011-05-12 |